



The 44th Annual  
High Country  
Nuclear  
Medicine  
Conference

March 10-14, 2023  
Sun Valley Inn | Sun Valley, ID

Saturday, March 11, 2023

All session times are in Mountain Time

6:30 AM – 7:00 AM

Breakfast with the Vendors

7:00 AM – 9:30 AM

**Alpha Therapy**

The talks will discuss the current status of alpha therapy, including availability and what agents are likely to be approved in the near future

**Session Chair: Andreas Kjaer, MD, PhD, DMSc, MBA**

**Co-Chair: Michael Graham, MD, PhD**

**Session Topics:**

**Isotope Availability Now and in the Future - Focus on Alphas**

*Speaker: Roy Brown, MBA*

**Targeted alpha therapy in neuroendocrine tumors: results from <sup>212</sup>Pb-DOTAMTATE clinical trials**

*Speaker: Dr. Ebrahim Delpassand, MD*

**VMT-alpha-NET - why does it have to be alpha?**

*Speaker: Frances Johnson, MD*

**<sup>211</sup>At - an Ideal Alpha Emitter?**

*Chair: Andreas Kjaer, MD, PhD*

1:00 PM – 3:00 PM

**Roundtable: General Oncology**

We will discuss the latest papers on FAPI, covering both diagnostic and therapeutic applications. Other topics may be discussed, depending on participant interests.

**Chair: Mike Graham, MD, PhD**

4:00 PM – 7:30 PM

**Prostate Update**

In this session, we will discuss the role of nuclear medicine in evaluating and treating patients with advanced prostate cancer. We will review the appropriate use criteria for PSMA PET/CTs, the use of radioligand therapy in the clinic, and the future of theranostics. We as well discuss the critical steps in opening a theranostic center.

**Session Chair: Bitai Savir-Baruch, MD**

**Co-Chair: Jeremie Calais, MD, MSc / Michael Graham, MD, PhD**

**Session Topics:**

**PSMA PET- Appropriate use criteria and patient selection for radioligand therapy**

*Speaker: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI*

**Therapy of prostate cancer with Lu177-PSMA**

*Speaker: Tom Hope, MD*

**Radioligand therapy Beyond Vision and TheraP trials- Review of clinic trials for Prostate cancer**

*Speaker: Jeremie Calais, MD, MSc*

**How to build and design a Theranostic center**

*Chair: Bital Savir-Baruch, MD, FACNM*

**Sunday, March 12, 2023**

**All session times are in Mountain Time**

**6:30 AM – 7:00 AM**

**Breakfast with the Vendors**

**7:00 AM – 9:30 AM**

**Cutting Edge Nuclear Cardiology**

This session will outline the contemporary role for cardiac PET and SPECT in disease diagnosis and risk stratification. The speakers will highlight the latest advances in clinical nuclear cardiology which will enable nuclear Cardiology to retain a prominent role in the management of patients with known or suspected coronary artery disease.

**Session Chair: Rob Miller**

**Co-Chair: Dan Berman, MD**

**Session Topics:**

**Guidelines for Chest Pain Imaging: Where do SPECT and PET fit in?**

*Speaker: Dennis Calnon, MD, FACC, FASE, MASNC, FSCCT*

**PET Myocardial Perfusion Imaging and Flow:**

*Speaker: Krishna K. Patel, MD, MSc*

**F-18 Flurpiradaz Perfusion Imaging; the Time is Now**

*Speaker: Jamshid Maddahi, MD, FACC, FASNC*

**F-18 Sodium fluoride; applications in coronary disease**

*Speaker: David Newby, PhD*

**Enhancing SPECT: flows, CAC, quantitation**

*Speaker: Robert Miller*

**1:00 PM – 3:00 PM**

**Roundtable: Discussing the Future of Nuclear Cardiology**

During this interactive session, speakers will discuss the future landscape for nuclear Cardiology. This forward-looking session will provide an overview of emerging applications including potential future directions for cardiac PET, the important role for nuclear Cardiology in infiltrative cardiomyopathies, and novel PET radiotracers with non-coronary applications.

**Lead: Rob Miller**

**Co Chair: Dan Berman, MD**

**Session Topics:**

**Where to take cardiac PET after CAC and flows**

*Speaker: Piotr Slomka, PhD*

**Hybrid imaging in cardiac amyloidosis and sarcoidosis**

*Speaker: Robert Miller*

**Emerging novel tracers including GP1, FAPI, and valvular applications of F18**

*Speaker: David Newby, PhD*

**4:00 PM – 6:30 PM**

**Instrumentation**

We will review the latest advances in the nuclear medicine instrumentation, including total body PET, digital and other novel PET designs as well as latest generation of SPECT/CT scanners.

**Session Chair: Piotr Slomka, PhD**

**Co-Chair: Ramsey Badawi, PhD**

**Scheduled Topics:**

**PhD Whole Body PET**

*Speaker: Ramsey Badawi, PhD*

**Digital PET**

*Speaker: Keisha McCall, PhD*

**Latest developments in digital CZT SPECT**

*Speaker: Benjamin Auer, PhD*

**Latest SPECT developments**

*Speaker: Hans Vija*

**7:00 PM – 9:00 PM**

**Sunday Night Dinner & Hal O'Brien Rising Star Award Ceremony**

Open to all in-person attendees with meeting registration. Additional tickets available for guests.

**Monday, March 13, 2023**

**All session times are in Mountain Time**

**6:30 AM – 7:00 AM**

**Breakfast with the Vendors**

**7:00 AM – 9:30 AM**

**Policy and Regulatory Updates**

Federal legislative and regulatory activity related to nuclear medicine remains robust, with recent significant developments such as passage of new drug pricing legislation within the Inflation Reduction Act. A number of important regulatory initiatives have been or will be underway within the Nuclear Regulatory Commission. The mid-term elections

have result in split control of the Congress. This session will provide updates regarding an overview of ongoing legislative and regulatory changes impacting the nuclear medicine sector.

**Session Chair: Ira Goldman, MA**

**Co-Chair: Cathy Cutler**

**Scheduled Topics:**

**SNMMI Update**

*Speaker: Cathy Cutler*

**Reimbursement hot topics**

*Speaker: Denise Merlino, CNMT, CPC, MBA*

**FIND Act update**

*Speaker: Ira Goldman, MA*

**PAMA/AUC Update**

*Speaker: Kathy Flood*

**Current NRC nuclear medicine topics including Emerging Medical Technologies**

*Speaker: Christian Einberg*

**1:00 PM – 3:00 PM**

**Roundtable: Barriers to Access/Equity & Diversity in Clinical Trials/Barriers to a more diverse workforce**

We will discuss current Diversity, Equity, and Inclusion activities in nuclear medicine and molecular imaging as well as possible ways to increase diversity in the nuclear medicine community.

**Session Chair: Thomas Ng, MD**

**4:00 PM – 7:30 PM**

**Neuroimaging**

In this session we will discuss the use and role of PET tracers (beta amyloid and tau) in pivotal late stage Alzheimer's Disease (AD) clinical trials, as well as use and development of PET tracers in non-AD neurodegenerative diseases.

**Session Chair: Andrew Stephens, MD, PhD**

**Co-Chair: Maria Ponisio, MD**

**Scheduled Topics:**

**Update on AD clinical trials and the role of imaging biomarkers**

*Speaker: Mike Pontecorvo, PhD*

**Relationship between tau deposition and the functional network architecture of the brain**

*Speaker: Nicolai Franzmeier, PhD*

**Neuroimaging in CTE/TBI**

*Speaker: Mike Alosco, CTE*

**Imaging primary tauopathies and movement disorders**

*Speaker: Andrew Stephens, MD, PhD*

**New tracers for imaging neuroinflammation and tau**

*Speaker: Neil Vasdev, PhD*

**Tuesday, March 14, 2023**

**All session times are in Mountain Time**

**6:30 AM – 7:00 AM**

## Breakfast with the Vendors

**7:00 AM – 9:30 AM**

### **AI/machine learning**

Latest AI developments applied to nuclear medicine will be presented with examples in nuclear cardiology including the clinical perspective, PET brain imaging, and automated segmentation of oncological images.

**Session Chair: Piotr Slomka, PhD**

**Co-Chair: Joyita Dutta, PhD**

#### **Scheduled Topics:**

##### **AI-Enabled PET Imaging for Alzheimer's Disease**

*Speaker: Joyita Dutta, PhD*

##### **AI-powered nuclear cardiology**

*Chair: Piotr Slomka, PhD*

##### **How AI can help cardiovascular imaging clinicians**

*Speaker: Rob Miller, MD*

##### **Addressing clinical challenges in prostate cancer with an automated AI-based analysis of PSMA prostate images**

*Speaker: Sai Duriseti, MD*

**2:30 PM – 3:45 PM**

### **Roundtable: AI**

**4:00 PM – 7:30 PM**

### **Controversies in Thyroid Cancer Therapy**

Although we have been treating thyroid cancer with I-131 for 70 years, we still cannot agree on the best way.

**Session Chair: Michael Wissmeyer, MD, PhD**

**Co-Chair: Mike Graham, MD, PhD**

#### **Scheduled Topics:**

##### **Recombinant human thyrotropin versus thyroid hormone withdrawal in the management of differentiated thyroid cancer: examining the evidence**

*Speaker: Jennifer Kwak, MD*

##### **Update on the 2022 Joint SNMMI-EANM Thyroid Cancer Guidelines**

*Speaker: Anca Avram, MD*

##### **Radioiodine in differentiated thyroid carcinoma, an ever hot topic**

*Speaker: Michael Kreissl, MD*

##### **The Swiss consensus in low risk thyroid carcinoma**

*Speaker: Michael Wissmeyer, MD, PhD*